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The development of a therapeutic vaccine against human papillomavirus (HPV) is important for the 
control of cervical cancer. E7 is the major transforming protein produced in cervical cancers, and therefore 
represents potential tumor-specific antigen that could be the target of immunotherapy for cervical cancer. 
Among different vaccine strategies, protein-based vaccines are capable of generating CD8+ T cell responses 
in vaccinated animals and humans. Recently, development of novel strategies that enhance protein vaccine 
potency is important for generation of effective cancer vaccines and immunotherapies. Heat shock proteins 
(HSPs) including Gp96 have been shown to act as potent immuno-adjuvant to enhance antigen-specific 
tumor immunity. Therefore, the HSP-based protein vaccines can be administered by fusing antigens to 
HSPs, in vitro. It has been known that the HSP fragments (e.g., N-/or C-terminal regions) as mini-
chaperones are better choice for immunization. The most straightforward method to produce large amounts 
of recombinant protein suitable for a vaccine is to clone the gene into a prokaryotic expression vector and 
produce the protein in Escherichia coli. In current study, we describe cloning of the HPV16 E7 gene linked 
to C-terminal fragment of gp96, identification and purification of the resultant E7-CT (gp96) fusion protein 
for next usage as a potential vaccine candidate protein against HPV in a pre-clinical trial. The recombinant 
E7-CT (gp96) migrated as a 51 kDa protein in SDS-PAGE. In Western blot experiment, the existence of a 
51 kDa band for rE7-CT (gp96) was confirmed by rabbit anti-His as well as mouse anti-HPV16 E7 
monoclonal antibodies. The protein of interest was both in the insoluble and the soluble fraction; therefore, 
purification was performed under denaturating and native conditions by affinity chromatography on Ni-NTA 
resin using 6xHis-tag. 
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INTRODUCTION  
Human papillomavirus (HPV) belongs to the 
Papillomaviridae family and is a small virus 
formed by 72 pentameric capsomeres, 55nm in 
diameter [1]. Human papillomavirus (HPV) has 
been recognized as the primary cause of cervical 
cancer, and HPV DNA can be detected in 90% of 
all cases [2]. HPV 16, which is the most prevalent 
strain, has been detected in >50% of cervical 
cancer patients [3]. The HPV 16 genome is 
composed of three regions: 1) early genes (E1, 
E2, E4, E5, E6, and E7) that encode proteins 
responsible for transcription, replication and 
interaction with the host’s genome; 2) late genes 
(L1 and L2) encoding mainly capsid proteins 
responsible for the differentiation of HPV types 
[4]. The gene products of two HPV16 early open 
reading frames (ORF), E6 and E7, are together 
sufficient to immortalize human keratinocytes in 
 
Journal of Paramedical Sciences (JPS)                                              Spring 2012,Vol.3, No.2 ISSN 2008-4978 
3 
 
vitro [5]. E7 is the major transforming protein 
produced in cervical cancers, and therefore 
represents potential tumor-specific antigen that 
could be the target of immunotherapy for cervical 
cancer and pre-cancer [5]. Among different 
vaccine types, the protein/peptide vaccines appear 
to be the most promising and effective [6]. The 
major advantage of protein-based vaccines is that 
in principle they offer a high level of safety. HPV-
specific therapeutic vaccines based on proteins 
have been shown to be well-tolerated in humans, 
without the occurrence of significant adverse 
effects [7, 8]. On the other hand, the weak 
induction of cell-mediated immunity by these 
vaccines may present a major problem to induce 
an effective anti-tumor response in cervical cancer 
patients. Therefore, efforts have been made to 
enhance their potency through the use of 
adjuvants or specific antigen-delivery strategies 
[9]. Currently, the efficiency of protein vaccines 
has been increased through fusion with heat shock 
proteins (HSPs) [10]. Up to now, several HSP 
family members including Hsp70, Hsp90 and 
Gp96 have been utilized in cancer vaccine 
research. Gp96, an endoplasmic reticulum (ER) 
molecular chaperone, has been determined as a 
potent adjuvant for eliciting immune responses in 
vaccine development against different disorders 
[11-14]. Gp96 contains an N-terminal signal 
sequence, characteristic of the ER-targeted 
proteins and a carboxyl terminal KDEL sequence 
(Lys-Asp-Glu-Leu), which is a retention/retrieval 
signal from the golgi to the ER. The gp96 
fragments (i.e., N- and C- terminal of gp96) as 
mini-chaperones are better choice for 
immunization [15, 16]. 
Since HPV cannot be propagated in tissue 
culture to purify oncoproteins, therefore, it will be 
based on production of recombinant proteins in 
viral or bacterial expression systems. Currently, 
the most straightforward method to produce large 
amounts of recombinant protein suitable for a 
vaccine is to produce the protein in Escherichia 
coli. In this study, HPV16 E7 gene fused to C-
terminal fragment of gp96 was cloned into the 
expression vector pQE30. The recombinant 
protein of E7-CT (gp96) was expressed and 
purified in E. coli for HPV vaccine design in 
future. 
  
MATERIALS AND METHODS 
Generation of the recombinant E7-CT (gp96) 
protein [rE7-CT (gp96)]    
The C-terminal fragment of gp96 gene was 
obtained from the pQE30  vector containing the 
coding sequence of CT (gp96) protein [previously 
prepared by Bolhassani et al., 2009; Ref. 17]. For 
obtaining pUC-E7-CT (gp96) construct, the DNA 
encoding the C-terminal fragment of gp96 [~ 768 
bp] was cloned into the SmaI and SacI  sites of 
pUC-E7-NT (gp96) [previously provided in 
Molecular immunology and Vaccine Research 
lab]. Two pairs of primers (MWG Biotech GmbH, 
Germany) were designed (the SmaI and SacI 
restriction sites have been shown in bold). The 
forward and reverse primers for amplifying the 
CT (gp96) [CT1 & CT2] was designed as follows: 
CT1: 5' CGG CCC GGG GAG TCC TCT CCA 
TTT GTT GAA 3' 
CT2: 5' AT GAG CTC GGT ACC CAG TTC 
ATC TTT TAC ATC 3'  
   
  PCRs were performed by PCR thermal 
cycler (Techne, USA) under standard conditions 
(95°C for 1 min; 63°C for 1 min and 72°C for 1.5 
min; 30 cycles) and the products were separated 
on a 0.8 percent agarose gel. The bands 
corresponding to the expected PCR products size 
were gel purified (QIAquick gel extraction kit 
protocol, QIAGEN), digested with SmaI and SacI 
and ligated into a similarly digested expression 
plasmid pUC-E7-NT (gp96). The ligation mixture 
was used to transform E.coli DH5α strain. 
Plasmid DNA [pUC-E7-CT (gp96)] was purified 
from recombinant clones by an alkaline lysis 
method (Qiagen Plasmid Mini-Kit) verified by 
restriction enzyme digestion and sequenced using 
the dideoxy chain termination method on an 
automated sequencer. After confirmation of 
construct, the E7-CT (gp96) gene was excised 
from the pUC-E7-CT (gp96) vector by BamHI 
and SacI, gel purified and sub-cloned into the 
pQE-30 vector (Qiagen), which enables the 
expression of a fusion protein with a 6xHis-tag at 
N-terminus. The E. coli M15 strain was 
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transformed with pQE-E7-CT (gp96) and grown 
at 37˚C in LB broth supplemented with 100 μg/ml 
ampicillin and 25 μg/ml kanamycin. For the 
production of recombinant E7-CT (gp96), the 
cultures were grown to an optical density of 0.6–
0.8 at 600 nm and protein expression was induced 
with 1 mM IPTG for 2, 4 & 18 h at 37˚C. Protein 
samples were analyzed by SDS-PAGE in 12.5% 
(W/V) polyacrylamide gel (SDS gel apparatus; 
BioRad), followed by staining with coomassie 
brilliant blue. For western blot analysis, the 
proteins resolved on the gel were transferred onto 
protran nitrocellulose transfer membrane 
(Schleicher and Schuell Bioscience, Dassel, 
Germany). The membrane was pre-equilibrated 
with TBST solution [10 mM Tris–HCL (pH 7.4), 
150 mM NaCl, and 0.1% Tween 20] containing 
2.5% bovine serum albumin (BSA) overnight and 
then reacted with anti-His antibody (QIAGEN) 
and/or mouse anti-HPV16 E7 (monoclonal 
antibody, USBiological) for 2 h at room 
temperature. After three washes with TBST, the 
membrane was incubated with anti-mouse IgG-
HRP (1:2000, Sigma) for 1.5 h at room 
temperature. The immunoreactive protein bands 
were visualized using peroxidase substrate 3, 3'-
Diaminobenzidine (DAB, Sigma).  
 
Purification and assay of the recombinant 
protein    
The recombinant E7-CT (gp96) protein was 
purified by affinity chromatography [fast protein 
liquid chromatography (FPLC)] on Ni-NTA resin 
column (nickel-nitrilotriacetic acid) using 6xHis-
tag according to the manufacturer’s instructions 
(Qiagen protocol). Purification of recombinant E7 
protein was done under native and denaturing 
conditions. Briefly, the recombinant protein can 
be purified by Ni-NTA chromatography based on 
the interaction between a transition Ni
2+
 ion 
immobilized on a matrix and the histidine side 
chains. Following matrix washing, 6x Histidine-
tag fusion protein is eluted by adding free 
imidazole or EDTA or by reducing the pH. The 
purified proteins showed higher concentrations in 
native method than denaturing, but with 
additional bands. Therefore, in native method, an 
imidazole–SDS–Zn reverse staining method was 
used for further purification. Then, the purified 
protein fraction was concentrated by ultrafiltration 
(Amicon) and dialyzed against PBS (dialysis 
membrane, MWCO: 3.500 kDa, Spectrum). 
Protein concentration was measured using BCA 
assay kit (Pierce, Rockford, USA). The 
recombinant protein was kept at -70˚C until use.   
 
RESULTS 
Cloning of E7-CT (gp96) in E. coli expression 
system 
For preparation of the E7-CT (gp96) fusion 
gene, the C-terminal of gp96 [~768 bp] was 
generated by PCR and inserted into the cloning 
vector pUC-E7-NT (gp96). Plasmid DNA sample 
[pUC-E7-CT (gp96)] was purified by an alkaline 
lysis method and then sequenced. Then, the E7-
CT (gp96) gene sub-cloned into the expression 
pQE-30 vector, which enables the expression of a 
fusion protein with a 6xHis-tag at N-terminus. 
Figure 1 shows the DNA analysis of E7-CT 
(gp96) using PCR and digestion by the 
appropriate restriction enzymes (BamHI/SacI). 
 
 
Figure 1. The confirmation of PCR (2) and Digestion 
(3) of E7-CT (gp96) fusion gene [~1060 bp] in pQE30; 
Molecular weight marker (1 kb, fermentase co.) is 
indicated as MW in figure. H2O was used as a negative 
control in PCR (1). 
  
Expression and purification of the 
recombinant E7-CT (gp96) protein  
The recombinant E7-CT (gp96) protein was 
expressed and purified in E. coli. The rE7-CT 
(gp96) migrated as a 51 kDa protein in SDS-
PAGE (Figure 2A). Western blot analysis was 
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performed using anti-His/or anti-E7 antibody to 
ensure the proper expression of rE7-CT (gp96). A 
specific band with expected size (51 kDa) was 
detected in the induced bacterial lysate (Figure 
2B), although a few non-specific bands were also 
observed in both samples before and after IPTG 
induction with anti-His antibody. The additional 
bands were disappeared using anti-E7 monoclonal 
antibody due to further specificity (Figure 2B). 
Purification of rE7-CT (gp96) was done under 
denaturating and native conditions using affinity 
chromatography as shown in Figure 3. Purified 
samples were also confirmed by western blot 
analysis (Figure 2B). The obtained recombinant 
protein using native method was further purified 
by reverse staining method [data not shown]. 
Total protein concentrations of the samples were 
measured using a bicinchoninic acid (BCA) 
protein assay kit for next experiments.   
 
DICSUSSION 
Therapeutic vaccines targeting E6 and E7 
may provide the best option for controlling HPV-
associated malignancies. Most studies focus on 
E7, because it is more abundantly expressed and 
better characterized immunologically. 
Furthermore, its sequence is more conserved than 
that of the E6 gene [18]. Among different vaccine 
strategies, protein-based HPV vaccines have been 
tested in pre-clinical/or clinical trials. Clearly, 
generation of humoral and cellular immune 
responses is influential parameters for designing 
ideal protein vaccine. The potency of HPV16 E7 
peptide/protein-based vaccines may be further 
enhanced through the use of adjuvants e.g., heat 
shock proteins (HSPs) [19, 20]. Heat shock 
proteins have been described as important 
immuno-stimulatory molecules to enhance 
antigen-specific tumor immunity. It was 
demonstrated that the ability of gp96 to facilitate 
cross-presentation of chaperoned antigen by 
interacting with CD91 which leads to specific 
potent T cell response has been conserved 
between the amphibian Xenopus and mammals 
[15]. However, Heat shock proteins-based 
vaccines are a novel approach with a promising 
role in cancer therapy.   
In current study, the recombinant HPV16 E7 
linked to C-terminal of gp96 was expressed and 
purified in E.coli expression system. In general, 
production of proteins, whether for biochemical 
analysis, therapeutics or structural studies, 
requires the success of three individual factors: 
expression, solubility and purification. Although, 
a number of expression hosts are available for 
protein production, the standard in the field still 
remains E. coli. Indeed, E. coli has significant 
benefits of cost, ease of use and scale, all of which 
make it suitable to use ways to generate 
heterologous proteins. Improving the generation 
of recombinant proteins in E. coli commonly 
involves changing some of the expression 
conditions: factors such as temperature, changes 
in the E. coli expression strain, different 
promoters or induction conditions, and co-
expression of molecular chaperones and folding 
modulators [21]. Nowadays, there are a number of 
common fusion tags that are used to increase the 
efficiency of protein purification in E. coli, e.g., 
hexa-histidine (His6) tag.   
Herein, the HPV16 E7-CT (gp96) gene was 
cloned into the bacterial expression vector (pQE-
30). Electrophoresis analysis of IPTG-induced 
cell lysates showed the presence of a prominent 
protein band that was not detectable in non-
induced cell lysates. In the presence of sodium 
dodecyl sulphate and 2- mercaptoethanol, the E7-
CT (gp96) protein migrated as a 51 kDa protein 
during poly acrylamide gel electrophoresis. Based 
on SDS-PAGE analysis, the expression of E7-CT 
(gp96) protein was found to be almost disturbed 
between soluble and insoluble fractions. 
Therefore, the purification of rE7-CT (gp96) 
could be done using affinity chromatography 
under native and denaturing conditions. The 
method used to purify E7-CT (gp96) fusion 
protein has been scaled up for large scale 
production of this protein to obtain the necessary 
quantity required for a vaccine design against 
HPV.  
 




                                        (2A)                                                                           (2B) 
 
Figure 2. Expression of E7-CT (gp96) protein in E. coli expression system: (A) The E7-CT (gp96) gene was cloned 
into the pQE-30 expression vector. Analysis of recombinant protein was done by SDS-PAGE and Western blotting. 
The recombinant HPV16E7-CT (gp96) protein was run on a polyacrylamide gel electrophoresis (12.5%) and stained by 
coomassie blue. The weight of the molecular mass markers (MW: Premixed protein molecular weight marker: 14.4- 
97.4 kDa) is indicated as MW in figure. Lysate of un-induced (B.I./Before Induction) and isopropyl-beta-D-
thiogalactopyranoside (IPTG, 1 mM) induced culture of E.coli (A.I./After Induction) in different times (2, 4, 18 hr) are 
shown on line 1-4 for empty vector (pQE30) and 5-8 for pQE-E7-CT (gp96), respectively. (B) Western blot analysis 
for the recombinant E7-CT (gp96) protein using anti-His antibody (1: B.I., 2: A.I., 3: purified protein) and anti-E7 




Figure 3. Purified recombinant protein by 
affinity chromatography using Ni-NTA 
resin: SDS-PAGE electrophoresis of lysate 
of un-induced (lane 1) and IPTG (1 mM) 
induced (lane 2) culture of E. coli and the 
recombinant protein purified by affinity 
chromatography using Ni-NTA resin under 








     The present study indicated the efficient 
production of E7-CT (gp96) protein in a 
prokaryotic expression system. This recombinant 
protein will be used for vaccine design against 
HPV in future. 
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